Data about FDA special protocol assessments might help public

02/9/2010 | Forbes

Though the FDA promised to be more transparent, legislation might be necessary to require the agency to disclose special protocol assessments with drugmakers, according to this blog. By making SPAs public, investors can become aware of the progress of drug trials, raising their confidence in their investments, the blog notes. Because the FDA treats SPAs as confidential, investors of Cell Therapeutics were unaware that the company's SPA was no longer valid, causing shares to drop 40% on Monday.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC